Achieve Life Sciences IncACHV
Price$8.09

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$114MTTM through 30 Jun 2026
Free Cash Flow -$47MTTM through 30 Jun 2026

Margins

Current

Returns

-487.7%ROE
-130.8%ROA

Balance Sheet Health

Debt / Equity1.40x
Current Ratio2.62x
Net Debt-$14.4Mnet cash position
Cash & Equivalents$48M

Quality Metrics

Altman Z-Score-0.33
Piotroski F-Score2 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'18'19
FY2019: $0
Diluted EPS-$1.66TTM
'20'21'22'23'24'25
FY2025: $-1.25

Dividend

No dividend

Capital Allocation

R&D Spend$26.4M

Segment Performance

SegmentRevenueYoYOutlook
Cytisinicline Development$0
View details

Targeting U.S. commercial launch in the first half of 2027 with manufacturing partner Adare Pharma Solutions.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.